Venture Capital Firm I Home
Innovation.
Clarity.
Execution.
A Venture Capital Firm for Visionary Innovators.
Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA.
We are a highly experienced team with a long-standing track record of entrepreneurial and investment success. We do this by turning break-through science into approved medicines or medical products.
We start and invest in early and mid-stage companies with a first-in-class or best-in-class approach.
Our investments are focused on new drug discovery across all modalities, med tech, enabling technologies and vaccines.
About
As entrepreneurs and experienced, pragmatic investors, we bring the intellectual capital of our well-connected team to support each investment.
We take a hands-on approach and work in close alignment and partnership with our management teams to realise their vision with the goal of achieving superior financial returns by bringing innovation to patients.
Team
Innovation.
We are backing exceptional innovation early.
Since the year 2006, Advent-backed companies have brought fifteen innovative medicines and products to approval with our initial investment often being as early as Seed stage or Series A.
As the mid- and late-stage clinical pipelines of our portfolio companies continue to grow, this number looks set to increase each year.
Portfolio
Latest Press Releases
Pheno Therapeutics granted FDA IND clearance for lead multiple sclerosis therapeutic candidate PTD802
Press Release. PRESS RELEASE 22 June 2026 Pheno Therapeutics granted FDA IND clearance for lead multiple sclerosis therapeutic candidate PTD802 US FDA clearance enables first-in-human study of PTD802, a…
Read More
F2G and Shionogi Announce Positive Topline Results from Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients with Invasive Aspergillosis
Press Release. F2G and Shionogi Announce Positive Topline Results from Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients with Invasive…
Read More
Amphista Therapeutics announces FDA clearance of IND application for AMX-883, its lead Targeted Glue™ degrader for acute myeloid leukaemia
Press Release. Amphista Therapeutics announces FDA clearance of IND application for AMX-883, its lead Targeted Glue™ degrader for acute myeloid leukaemia June 8, 2026 Amphista to initiate its first…
Read More
